Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Bristolmyers squibb | Mind Blowing Facts

Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Two Straddles Define Wednesday’s Unusual Options Activity Across Key Stocks

Among Wednesday’s 35 most unusually active options, two emerged as notable straddle setups appealing to both bullish and bearish traders. These potential plays revolve around some of the market’s most familiar and widely followed stocks.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

The Saturday Spread: Using the ‘Taxonomical’ Approach to Extract Profits

While fundamental and technical analyses dominate the finance ecosystem, there’s another, more powerful mechanism to succeed in the markets.

Barchart

ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Malcolm Ethridge, managing partner at Capital Area Planning Group, said ServiceNow, Inc. (NYSE:NOW) is around 25% off its 52-week high. It has become a victim of its own success, so it’s probably creating an attractive entry point, he added.

Benzinga

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Although Bristol-Myers Squibb has outshined relative to the healthcare sector over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

Barchart

Read news from The Economist, FT, and more,
with one subscription

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Euronews

Stocks Rise Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.20%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.10% this morning, suggesting Wall Street is set to extend yesterday’s gains, while investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from…

Barchart

Stocks Muted Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

Barchart

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

Is Bristol-Myers Squibb Stock Outperforming the Nasdaq?

Although Bristol-Myers Squibb has outperformed the broader Nasdaq index over the past three months, analysts remain cautious about its growth prospects.

Barchart

What's Behind the Insider Buying on This High-Yield Stock?

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

Barchart

Bristol-Myers Squibb's Q2 2024 Earnings: What to Expect

Bristol-Myers Squibb is poised to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Healthcare Stocks With The Highest Yields As of June 2024

Looking for yield? Here's 3 healthcare stocks with the highest yields today.

Barchart

Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

Bristol-Myers Squibb stock has significantly trailed the broader market this year, and Wall Street remains wary on the stock’s prospects.

Top News

Bristol Myers Surpasses Expectations with Q4 Results

Bristol Myers has reported better-than-expected 4th-quarter results, indicating positive performance for the company.

Fortune

Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial Medicare price talks. But any relief is still years away

The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stocks Climb Before the Open as Investors Await Key U.S. GDP Data, Meta Results Boost Sentiment

September S&P 500 futures (ESU23) are up +0.59%, and September Nasdaq 100 E-Mini futures (NQU23) are up +1.20% this morning after three major U.S. benchmark indices ended the regular session mixed as market participants digested Federal Reserve Chair Jerome Powell’s comments following the Fed’s widely expected 25 basis point rate…

Benzinga

A Look Into Bristol-Myers Squibb's Debt

Over the past three months, shares of Bristol-Myers Squibb Inc. (NYSE:BMY) rose by 2.13%. Before we understand the importance of debt, let's look at how much debt Bristol-Myers Squibb has.

The Conversation

Should you really use your smartwatch or fitness wearable to monitor your heart?

Wearable devices that can record your pulse can be handy for tracking your fitness – but can you really use them to monitor for an irregular heartbeat?

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 17 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022

Upgrades

Benzinga

Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock

The Nasdaq Composite dropped by around 150 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

What Are Whales Doing With Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.